Video

Dr. Pulliam on future research for the leva Pelvic Health System

“leva can help women successfully do pelvic floor muscle training and experience symptom resolution,” says Samantha Pulliam, MD.

In this video, Samantha Pulliam, MD, discusses future research on the leva Pelvic Health System as well as take-home messages from the Obstetrics & Gynecology study, “Digital therapeutic device for urinary incontinence: a randomized controlled trial.” Pulliam is chief medical officer for Renovia Inc.

Related Videos
Dean S. Elterman, MD, MSc, FRCSC, answers a question during a Zoom video interview
Vanita Gaglani, RPT, answers a question during a video interview
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
William Furuyama, MD, answers a question during a Zoom video interview
Related Content
Published OASIS data show durable efficacy of Revi System for UUI
February 7th 2025

Published OASIS data show durable efficacy of Revi System for UUI

Hannah Clarke
At 24 months, 79% of patients experienced a response to therapy, and 56% achieved at least a 75% reduction in UUI episodes.
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff
“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
Sunobinop shows promise in phase 1b trial for overactive bladder
January 7th 2025

Sunobinop shows promise in phase 1b trial for overactive bladder

Hannah Clarke
Sunobinop resulted in a reduction in urinary urgency, urinary frequency, and incontinence episodes over the treatment period compared with placebo.
Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB
March 18th 2022

Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

Urology Times staff
“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.
FDA approves vibegron for OAB symptoms in pharmacologically treated BPH
December 23rd 2024

FDA approves vibegron for OAB symptoms in pharmacologically treated BPH

Hannah Clarke
The approval of vibegron is supported by data from the phase 3 COURAGE trial.
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
December 17th 2024

Sexual QOL improved at 12 months following AUS placement

LeRoy Jones, MD
"I think this is a very important trial, just to bring some importance about patients' worries about being sexually active with urinary incontinence," says LeRoy Jones, MD.
© 2025 MJH Life Sciences

All rights reserved.